Onychomycosis Pipeline Insights, 2022 | In-depth Assessment into the Latest FDA, EMA, and PMDA Approvals, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithms, and Key Players by DelveInsight

As per DelveInsight's assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Onychomycosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Onychomycosis therapy aims to eliminate the infecting fungal organism and restore the nail to its normal state as it grows. Several treatment options are available for treating Onychomycosis, including oral antifungals, topical antifungals, and devices. Oral antifungals have higher treatment cure rates and shorter treatment periods than topical treatments but have adverse side effects such as hepatotoxicity and drug interactions. As per DelveInsight, the Onychomycosis market is anticipated to transform in the coming years owing to the increasing prevalent population of Onychomycosis and the expected entry of new therapies into the market.

"Onychomycosis Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Onychomycosis Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Onychomycosis Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Onychomycosis Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onychomycosis treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Onychomycosis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Onychomycosis Therapeutics Analysis
There are approx. 15+ key companies developing therapies for Onychomycosis. Currently, Moberg Pharma is leading the therapeutics market with its Onychomycosis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Onychomycosis Therapeutics Market Include:
- Moberg Pharma
- Blueberry Therapeutics
- DermBiont
- Sanotize Research and Development
- Meiji Seika Pharma
- NovaBiotics
- Polichem
- Hallux
- Hexima
- Turn Therapeutics
- Mycovia Pharmaceuticals
- CSA BioTech
- Kaken Pharmaceutical
- Turn Therapeutics
And Many More

Onychomycosis Emerging Drugs Covered in the Report Include:
- MOB‐015: Moberg Pharma
- BB2603: Blueberry Therapeutics
- NP213 (Novexatin): NovaBiotics Ltd.
- Hallux Terbinafine Subungual Gel (HSG): Hallux
And Many Others

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Onychomycosis Current Treatment Patterns
4. Onychomycosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Onychomycosis Late Stage Products (Phase-III)
7. Onychomycosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Onychomycosis Discontinued Products
13. Onychomycosis Product Profiles
14. Onychomycosis Key Companies
15. Onychomycosis Key Products
16. Dormant and Discontinued Products
17. Onychomycosis Unmet Needs
18. Onychomycosis Future Perspectives
19. Onychomycosis Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.